CL2020002139A1 - 7-substituted sulfonimidoylpurinone compounds and their derivatives for the treatment and prevention of liver cancer. - Google Patents

7-substituted sulfonimidoylpurinone compounds and their derivatives for the treatment and prevention of liver cancer.

Info

Publication number
CL2020002139A1
CL2020002139A1 CL2020002139A CL2020002139A CL2020002139A1 CL 2020002139 A1 CL2020002139 A1 CL 2020002139A1 CL 2020002139 A CL2020002139 A CL 2020002139A CL 2020002139 A CL2020002139 A CL 2020002139A CL 2020002139 A1 CL2020002139 A1 CL 2020002139A1
Authority
CL
Chile
Prior art keywords
treatment
liver cancer
prevention
derivatives
compounds
Prior art date
Application number
CL2020002139A
Other languages
Spanish (es)
Inventor
Thomas Poeschinger
Carola Ries
Hong Shen
Hongying Yun
Sabine Hoves
Carina Hage
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2020002139A1 publication Critical patent/CL2020002139A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I), en donde R1, R2 y R3 son como se describen en el presente documento, y sus profármacos o una sal farmacéuticamente aceptable, enantiómero o diastereómero de la misma, para (su uso en) el tratamiento y/o profilaxis del cáncer de hígado.The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof, for (their use in ) the treatment and / or prophylaxis of liver cancer.

CL2020002139A 2018-02-28 2020-08-19 7-substituted sulfonimidoylpurinone compounds and their derivatives for the treatment and prevention of liver cancer. CL2020002139A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28

Publications (1)

Publication Number Publication Date
CL2020002139A1 true CL2020002139A1 (en) 2021-01-04

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002139A CL2020002139A1 (en) 2018-02-28 2020-08-19 7-substituted sulfonimidoylpurinone compounds and their derivatives for the treatment and prevention of liver cancer.

Country Status (19)

Country Link
EP (1) EP3758707A1 (en)
JP (1) JP7089596B2 (en)
KR (1) KR20200128414A (en)
CN (1) CN111801100B (en)
AR (1) AR114419A1 (en)
AU (1) AU2019228654A1 (en)
BR (1) BR112020016509A2 (en)
CA (1) CA3091950A1 (en)
CL (1) CL2020002139A1 (en)
CO (1) CO2020010306A2 (en)
IL (1) IL276817A (en)
MA (1) MA52412A (en)
MX (1) MX2020008746A (en)
PE (1) PE20211456A1 (en)
PH (1) PH12020551343A1 (en)
RU (1) RU2020131012A (en)
SG (1) SG11202008291XA (en)
TW (1) TW202003518A (en)
WO (1) WO2019166432A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912715B2 (en) 2016-08-29 2024-02-27 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
US12071441B2 (en) 2018-02-28 2024-08-27 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102409595B1 (en) 2020-06-29 2022-06-17 한국과학기술연구원 Novel purinone derivatives as protein kinase CSF-1R inhibitor
CN112420196A (en) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 Prediction method and system for survival rate of acute myocardial infarction patient within 5 years
EP4554678A1 (en) * 2022-07-14 2025-05-21 F. Hoffmann-La Roche AG Phosphorylpurinone compounds for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (en) 1997-12-26 2008-12-03 大日本住友製薬株式会社 Heterocyclic compounds
RS53347B (en) 2008-12-09 2014-10-31 Gilead Sciences, Inc. TOLL-SIMILAR RECEPTOR MODULATORS
AU2010250923A1 (en) * 2009-05-21 2011-11-17 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
JP5694345B2 (en) * 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Regulators of TOLL-like receptors
US20110150836A1 (en) * 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
ES2691671T3 (en) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
KR20130108295A (en) * 2010-08-13 2013-10-02 베일러 리서치 인스티튜트 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
PL3294740T3 (en) 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
EP3368092B9 (en) 2015-10-29 2020-07-29 Novartis AG Antibody conjugates comprising toll-like receptor agonist
PL3504210T3 (en) 2016-08-29 2021-07-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
EP3512556B1 (en) * 2016-09-13 2021-08-18 F. Hoffmann-La Roche AG Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912715B2 (en) 2016-08-29 2024-02-27 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
US12071441B2 (en) 2018-02-28 2024-08-27 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza

Also Published As

Publication number Publication date
SG11202008291XA (en) 2020-09-29
CN111801100A (en) 2020-10-20
PE20211456A1 (en) 2021-08-05
MX2020008746A (en) 2020-09-28
CN111801100B (en) 2023-10-24
RU2020131012A (en) 2022-03-28
CA3091950A1 (en) 2019-09-06
EP3758707A1 (en) 2021-01-06
KR20200128414A (en) 2020-11-12
AU2019228654A1 (en) 2020-09-03
PH12020551343A1 (en) 2021-06-21
MA52412A (en) 2021-06-02
TW202003518A (en) 2020-01-16
JP2021514972A (en) 2021-06-17
JP7089596B2 (en) 2022-06-22
IL276817A (en) 2020-10-29
WO2019166432A1 (en) 2019-09-06
CO2020010306A2 (en) 2020-08-31
BR112020016509A2 (en) 2020-12-15
AR114419A1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
MX379474B (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
CO2019000932A2 (en) New 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of viral infection.
CL2020002139A1 (en) 7-substituted sulfonimidoylpurinone compounds and their derivatives for the treatment and prevention of liver cancer.
MX2022012313A (en) OXISTEROLS AND METHODS OF USE THEREOF.
MX394700B (en) Piperidine-substituted MNK inhibitors and methods related thereto.
UY36122A (en) ? DERIVATIVES OF PIRROLIDINA-2,5-DIONA, PHARMACEUTICAL COMPOSITIONS AND METHODS TO USE AS IDO1 INHIBITORS?
MX2020011449A (en) OXYSTEROLS AND METHODS OF USE THEREOF.
MX375970B (en) TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USES.
MX2018000280A (en) OXIESTEROLS AND METHODS OF USE OF THE SAME.
UY35617A (en) 3-QUINASA PHOSFATIDYLINOSITOL INHIBITORS
CO2017003838A2 (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
UY36170A (en) DIHYDROISOQUINOLINONA SUBSTITUTED COMPOUNDS
CO2017009994A2 (en) New compounds and derivatives of sulfonimidoylpurinone for the treatment and prophylaxis of viral infections
CR20170003A (en) DERIVATIVES OF INDANO AND INDOLINA AND THE USE OF THE SAME AS ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE
CU20170007A7 (en) IMIDAZOPIRIDAZINE COMPOUNDS
DOP2019000100A (en) DERIVATIVES OF NAFTIRIDINONE AND ITS USE IN THE TREATMENT OF ARRITMIA
CO2019002517A2 (en) Dopamine-β-hydroxylase inhibitors
ECSP16083017A (en) DERIVATIVES OF DIHETEROCICLO LINKED TO CYCLOALKYL
CO2017003225A2 (en) New 3-substituted 5-amino-6h-thiazolo [4,5-d] pyrimidine-2,7-dione compounds
SV2016005317A (en) DERIVATIVES OF PIRROLIDINE -2,5-DIONA, PHARMACEUTICAL COMPOSITIONS AND METHODS TO USE AS IDO1 INHIBITORS
CR20160532A (en) DERIVATIVES OF PIRROLIDINA-2,5-DIONA, PHARMACEUTICAL COMPOSITIONS AND METHODS TO USE AS IDO1 INHIBITORS